| 1. |
- Le Lay, G., et al.
(författare)
-
Nature of the root 3 alpha to 3 x 3 reversible phase transition at low temperature in Sn/Ge (111)
- 2001
-
Ingår i: Applied Surface Science. - 0169-4332 .- 1873-5584. ; 175, s. 201-206
-
Tidskriftsartikel (refereegranskat)abstract
- Metal-induced superstructures on semiconductors at sub-monolayer coverages have been mostly studied at, or above, room temperature. Yet, recently, several reversible phase transitions, like, e.g. the root3 x root3 alpha to 3 x 3 transition in the Pb, Sn/Ge (111) prototypical systems, have been discovered below RT. The origin of these new reconstructions is very intriguing and is a matter of strong debate. Some groups privilege electronic instabilities leading to charge ordered states at low temperature (LT), while other favor dynamical effects and the formation a kind of bond density waves (BDW's) at LT. Besides these intrinsic behaviors, the role played by inevitable defects has also been emphasized by several authors. Focussing especially on the Sn/Ge (111) system, we present a detailed analysis of the spectroscopic signatures of each phase in photoemission measurements. We show that static models are impossible to reconcile with these measurements.
|
|
| 2. |
- Rad, M. G., et al.
(författare)
-
Influence of charged impurities on the surface phases of Sn/Ge(111)
- 2001
-
Ingår i: Surface Science. - 0039-6028 .- 1879-2758. ; 477:03-feb, s. 227-234
-
Tidskriftsartikel (refereegranskat)abstract
- The root3 alpha and 3 x 3 reconstructions on the Ge(111)-Sn surface have been perturbed by small amounts of iodine and potassium to test the spectral response in the course of a synchrotron radiation photoemission study. We demonstrate the inadequacy of the static model of the root3 alpha phase at room temperature and of the surface charge density wave model of the 3 x 3 phase at low temperature. Instead, the influence of the charged impurities is consistently explained when considering that dynamical fluctuations in the tin adatom positions are frozen in upon passing the phase transition temperature.
|
|
| 3. |
- Risberg, Björn, et al.
(författare)
-
Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions : diagnostic and histogenetic implications
- 2002
-
Ingår i: International Journal of Gynecological Pathology. - Philadelphia, USA : Lippincott Williams & Wilkins. - 0277-1691 .- 1538-7151. ; 21:2, s. 155-160
-
Tidskriftsartikel (refereegranskat)abstract
- The objective of the present study was to analyze the expression of the proliferation marker, Ki-67, and the anti-apoptotic protein, bcl-2, in various endometrial lesions. Ki-67 and bcl-2 expressions were studied in 194 specimens of endometrial hyperplasia, polyps, carcinomas, and cyclic endometrium from a defined geographic area. Results were statistically analyzed with respect to marker expression, localization to the stromal or glandular component, and intraglandular topography. The lowest glandular Ki-67 expression was seen in secretory endometrium, in polyps, and in atypical hyperplasia. The Ki-67 score was significantly higher and less heterogeneous in endometrial carcinomas than in hyperplasia (p<0.001). Endometrial hyperplasia of all types was characterized by a markedly heterogeneous glandular expression of Ki-67. The glandular expression of bcl-2 was highest in proliferative endometrium and polyps. Bcl-2 expression was significantly lower in adenocarcinomas than in hyperplastic lesions (p=0.002). Ki-67 and bcl-2 expression showed a significant association in proliferative endometrium (p=0.003). Endometrial polyps demonstrated a unique pattern of very low expression of Ki-67 and high bcl-2 expression in both stroma and glands. Our findings indicate that an imbalance between proliferation and apoptosis may be an important factor in the development of different endometrial lesions, benign as well as malignant. The specific finding of inter- and intraglandular Ki-67 heterogeneity may be valuable as an adjunct to morphology in the differential diagnosis of endometrial hyperplasia.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Davila, M. E., et al.
(författare)
-
Surface phase transitions at metal-semiconductor interfaces : a revisit is needed
- 2004
-
Ingår i: Applied Surface Science. - : Elsevier BV. - 0169-4332 .- 1873-5584. ; 234:04-jan, s. 274-285
-
Tidskriftsartikel (refereegranskat)abstract
- In this article, we review some of the most recent progress and understanding in the low temperature surface phase transitions at prototypical metal-semiconductor interfaces. We essentially focus on quantitative surface structural information obtained by using a significant variety of specialised techniques for the individual phases of a model system, namely, tin on Ge(1 1 1) substrates. The strengths and limitations of the structural results obtained by using scanning tunnelling microscopy, photoelectron diffraction and surface X-ray diffraction are discussed in relation to their support with respect to possible mechanisms recently invoked in the literature as being at the origin of the phase transition. These investigations show that a large progress has been made in this field, taking into account the very valuable experimental and theoretical contributions provided by different groups. There remain, however, essential unresolved problems, which will be analysed in the light of the limitations of these structural methods and the difficulty presented by the complex adsorbate systems studied.
|
|
| 8. |
- Eriksson, Ulf G, et al.
(författare)
-
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran : a population model analysis
- 2003
-
Ingår i: Clinical Pharmacokinetics. - 0312-5963 .- 1179-1926. ; 42:7, s. 687-701
-
Forskningsöversikt (refereegranskat)abstract
- OBJECTIVE: Ximelagatran, an oral direct thrombin inhibitor, is rapidly bioconverted to melagatran, its active form. The objective of this population analysis was to characterise the pharmacokinetics of melagatran and its effect on activated partial thromboplastin time (APTT), an ex vivo measure of coagulation time, in orthopaedic surgery patients sequentially receiving subcutaneous melagatran and oral ximelagatran as prophylaxis for venous thromboembolism. To support the design of a pivotal dose-finding study, the impact of individualised dosage based on bodyweight and calculated creatinine clearance was examined. DESIGN AND METHODS: Pooled data obtained in three small dose-guiding studies were analysed. The patients received twice-daily administration, with either subcutaneous melagatran alone or a sequential regimen of subcutaneous melagatran followed by oral ximelagatran, for 8-11 days starting just before initiation of surgery. Nonlinear mixed-effects modelling was used to evaluate rich data of melagatran pharmacokinetics (3326 observations) and the pharmacodynamic effect on APTT (2319 observations) in samples from 216 patients collected in the three dose-guiding trials. The pharmacokinetic and pharmacodynamic models were validated using sparse data collected in a subgroup of 319 patients enrolled in the pivotal dose-finding trial. The impact of individualised dosage on pharmacokinetic and pharmacodynamic variability was evaluated by simulations of the pharmacokinetic-pharmacodynamic model. RESULTS: The pharmacokinetics of melagatran were well described by a one-compartment model with first-order absorption after both subcutaneous melagatran and oral ximelagatran. Melagatran clearance was correlated with renal function, assessed as calculated creatinine clearance. The median population clearance (creatinine clearance 70 mL/min) was 5.3 and 22.9 L/h for the subcutaneous and oral formulations, respectively. The bioavailability of melagatran after oral ximelagatran relative to subcutaneous melagatran was 23%. The volume of distribution was influenced by bodyweight. For a patient with a bodyweight of 75kg, the median population estimates were 15.5 and 159L for the subcutaneous and oral formulations, respectively. The relationship between APTT and melagatran plasma concentration was well described by a power function, with a steeper slope during and early after surgery but no influence by any covariates. Simulations demonstrated that individualised dosage based on creatinine clearance or bodyweight had no clinically relevant impact on the variability in melagatran pharmacokinetics or on the effect on APTT. CONCLUSIONS: The relatively low impact of individualised dosage on the pharmacokinetic and pharmacodynamic variability of melagatran supported the use of a fixed-dose regimen in the studied population of orthopaedic surgery patients, including those with mild to moderate renal impairment.
|
|
| 9. |
- Fernandes, Oswaldo J. C. B., et al.
(författare)
-
Prognostic factors for the survival of surgically treated patients for non-small cell lung cancer
- 2003
-
Ingår i: Acta Oncologica. - Oslo, Norway : Taylor & Francis. - 0284-186X .- 1651-226X. ; 42:4, s. 338-341
-
Tidskriftsartikel (refereegranskat)abstract
- The survival and outcome rates of 284 patients who underwent surgical treatment for non-small cell lung cancer were assessed retrospectively. Resectability rate was 94.1%, hospital mortality 3.9% (n = 11) and the mortality rates in patients who underwent pneumonectomy or lobectomy were 8.9% and 0.6%, respectively. The overall 5-year survival was 43.6%. Female gender, earlier stages of disease and a complete resection were strongly predictive for a long-term survival. Women in stage IA disease had a 5-year survival rate of 92.7%. The 5-year survival rate for patients in stages IIIA and N2 disease who underwent a complete resection was 21.9%, and 9% for those who did not undergo a complete resection. It is concluded that the best surgical results were observed in women who were operated on at an early stage of disease. A complete resection also contributed to a better outcome, even for patients in stage IIIA and N2 disease.
|
|
| 10. |
- Graflund, Marianne, et al.
(författare)
-
Immunohistochemical expression of p53, bcl-2, and p21WAF1/CIP1 in early cervical carcinoma : Correlation with clinical outcome
- 2002
-
Ingår i: International Journal of Gynecological Cancer. - Malden, USA : BMJ. - 1048-891X .- 1525-1438. ; 12:3, s. 290-298
-
Tidskriftsartikel (refereegranskat)abstract
- The objective of this study was to assess the value of p53, bcl-2, and p21WAF1/CIP1 immunoreactivity as predictors of pelvic lymph node metastases (LNM), recurrences, and death due to the disease in early stage (FIGO I-II) cervical carcinomas. FIGO stage, type of histopathology, and tumor grade were also evaluated in this series of patients treated by radical hysterectomy (Wertheim-Meigs) between 1965 and 1990. A total of 172 patients were included. A tumor was regarded as positive when more than 30% of the neoplastic cells exhibited immunoreactivity. Positive immunostaining was found in 8.9% for p53, in 43.5% for bcl-2, and in 25.0% for p21WAF1/CIP1. None of them was able to predict LNM or clinical outcome. Presence of LNM, tumor recurrence, and death from disease were significantly associated with the FIGO stage (P = 0.014, P = 0.009, and P = 0.001, respectively). The 5-year cancer-specific survival rate was 91.6% and the overall survival rate was 90.5%. It was concluded that immunohistochemically detected p53, bcl-2, and p21WAF1/CIP1 appeared to be of no predictive value with regard to LNM, tumor recurrences, or long-term survival in early cervical carcinomas.
|
|
